{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:13:44Z","timestamp":1792253624457,"version":"4.4.0"},"reference-count":141,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.cjca.2021.03.016","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:01:51Z","timestamp":1616803311000},"page":"1129-1150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":554,"title":["2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3281-7915","authenticated-orcid":false,"given":"Glen J.","family":"Pearson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Thanassoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arden R.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Couture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Dayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon A.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Genest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Gr\u00e9goire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Lonn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.B. John","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Manjoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"McPherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ngui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Eve","family":"Pich\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sievenpiper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Wray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2021.03.016_bib0001","first-page":"1263","article-title":"2016 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0002","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2021.03.016_bib0003","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM200007063430103","article-title":"Primary prevention of coronary heart disease in women through diet and lifestyle","volume":"343","author":"Stampfer","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2021.03.016_bib0004","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/CIRCULATIONAHA.106.621417","article-title":"Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid- lowering and antihypertensive medications","volume":"114","author":"Chiuve","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2021.03.016_bib0005","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jama.2011.1202","article-title":"Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial","volume":"306","author":"Jenkins","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2021.03.016_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.jand.2014.12.009","article-title":"Diet quality as assessed by the healthy eating index, the alternate healthy eating index, the dietary approaches to stop hypertension score, and health outcomes: a systematic review and meta-analysis of cohort studies","volume":"115","author":"Schwingshackl","year":"2015","journal-title":"J Acad Nutr Diet"},{"key":"10.1016\/j.cjca.2021.03.016_bib0007","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.000752","article-title":"Associations of glycemic index and load with coronary heart disease events: a systematic review and meta-analysis of prospective cohorts","volume":"1","author":"Mirrahimi","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjca.2021.03.016_bib0008","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ijcard.2014.07.080","article-title":"Vegetarian diet, Seventh Day Adventists and risk of cardiovascular mortality: a systematic review and meta-analysis","volume":"176","author":"Kwok","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0009","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa1200303","article-title":"Primary prevention of cardiovascular disease with Mediterranean diet","volume":"368","author":"Estruch","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2021.03.016_bib0010","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3945\/ajcn.113.076901","article-title":"Consumption of nuts and legumes and risk of incident ischemic heart disease, stroke, and diabetes: a systematic review and meta- analysis","volume":"100","author":"Afshin","year":"2014","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.cjca.2021.03.016_bib0011","doi-asserted-by":"crossref","first-page":"g4490","DOI":"10.1136\/bmj.g4490","article-title":"Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies","volume":"349","author":"Wang","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2021.03.016_bib0012","doi-asserted-by":"crossref","first-page":"f6879","DOI":"10.1136\/bmj.f6879","article-title":"Dietary fibre intake and risk of cardiovascular disease: systematic review and meta-analysis","volume":"347","author":"Threapleton","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2021.03.016_bib0013","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.amjcard.2014.12.015","article-title":"Meta-analysis of the association between whole grain intake and coronary heart disease risk","volume":"115","author":"Tang","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0014","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/archinte.167.10.999","article-title":"Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis","volume":"167","author":"Kodama","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2021.03.016_bib0015","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"312","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2021.03.016_bib0016","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"Cholesterol lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2021.03.016_bib0017","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1161\/CIRCULATIONAHA.115.018383","article-title":"Individualized statin benefit for determining statin eligibility in the primary prevention of cardiovascular disease","volume":"133","author":"Thanassoulis","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2021.03.016_bib0018","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(20)32332-1","article-title":"Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials","volume":"396","author":"Gencer","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2021.03.016_bib0019","series-title":"Canadian Guidelines for Cardiac Rehabilitation and Cardiovascular Disease Prevention: Translating Knowledge Into Action","year":"2009"},{"key":"10.1016\/j.cjca.2021.03.016_bib0020","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/bmj.39335.385301.BE","article-title":"Pre-eclampsia and risk of cardiovascular disease and cancer later in life: a systematic review and meta-analysis","volume":"335","author":"Bellamy","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2021.03.016_bib0021","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/CIRCULATIONAHA.118.036748","article-title":"Cardiovascular disease-related morbidity and mortality in women with a history of pregnancy complications","volume":"139","author":"Grandi","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2021.03.016_bib0022","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/heartjnl-2016-309671","article-title":"Recurrent pre-eclampsia and subsequent cardiovascular risk","volume":"103","author":"Auger","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2021.03.016_bib0023","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/S0140-6736(05)67726-4","article-title":"Cardiovascular Health After Maternal Placental Syndrome (CHAMPS): population-based retrospective cohort study","volume":"366","author":"Ray","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2021.03.016_bib0024","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1111\/1471-0528.13117","article-title":"Metabolic syndrome after pregnancies complicated by pre-eclampsia or small for gestational age: a retrospective cohort","volume":"122","author":"Al-Nasiry","year":"2015","journal-title":"BJOG"},{"key":"10.1016\/j.cjca.2021.03.016_bib0025","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1161\/HYPERTENSIONAHA.116.07907","article-title":"Markers of vascular dysfunction after hypertensive disorders of pregnancy: a systematic review and meta-analysis","volume":"68","author":"Grand'Maison","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2021.03.016_bib0026","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/ajh\/hpy069","article-title":"Circulating microRNAs implicate multiple atherogenic abnormalities in the long-term cardiovascular sequelae of preeclampsia","volume":"31","author":"Dayan","year":"2018","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2021.03.016_bib0027","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease. A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2021.03.016_bib0029","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fcvm.2019.00055","article-title":"Hypertensive disorders of pregnancy and subsequent cardiovascular disease: current national and international guidelines and the need for future research","volume":"6","author":"Gamble","year":"2019","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cjca.2021.03.016_bib0030","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S1701-2163(15)30841-0","article-title":"The maternal health clinic: a new window of opportunity for early heart disease screening and intervention for women with pregnancy complications","volume":"35","author":"Smith","year":"2013","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.cjca.2021.03.016_bib0031","doi-asserted-by":"crossref","first-page":"h1035","DOI":"10.1136\/bmj.h1035","article-title":"Statins and congenital malformations: cohort study","volume":"350","author":"Bateman","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2021.03.016_bib0032","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/bdra.20181","article-title":"Pregnancy outcomes after maternal exposure to simvastatin and lovastatin","volume":"73","author":"Pollack","year":"2005","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0033","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJM200404083501524","article-title":"Central nervous system and limb anomalies in case reports of first-trimester statin exposure","volume":"350","author":"Edison","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2021.03.016_bib0034","first-page":"151","article-title":"2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"29","author":"Anderson","year":"2013","journal-title":"Can J Cardiol"},{"issue":"23 suppl 1","key":"10.1016\/j.cjca.2021.03.016_bib0035","article-title":"Atherogenic lipoprotein particles in atherosclerosis","volume":"109","author":"Carmena","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2021.03.016_bib0036","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/CIRCULATIONAHA.105.567107","article-title":"Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study","volume":"113","author":"Kathiresan","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2021.03.016_bib0037","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.cjca.2021.03.016_bib0038","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2021.03.016_bib0039","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.108.804146","article-title":"Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction","volume":"118","author":"Langsted","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2021.03.016_bib0040","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/archinternmed.2012.3708","article-title":"Fasting time and lipid levels in a community-based population: a cross-sectional study","volume":"172","author":"Sidhu","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2021.03.016_bib0041","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2015.10.055","article-title":"Discordance between apolipoprotein B and LDL-cholesterol in young adults predicts coronary artery calcification: the CARDIA study","volume":"67","author":"Wilkins","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0042","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/CIRCULATIONAHA.119.041149","article-title":"Comparison of conventional lipoprotein tests and apolipoproteins in the prediction of cardiovascular disease","volume":"140","author":"Welsh","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2021.03.016_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta191000","article-title":"Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling","volume":"19","author":"Perera","year":"2015","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.cjca.2021.03.016_bib0044","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1373\/clinchem.2018.287037","article-title":"Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A consensus statement from EAS and EFLM","volume":"64","author":"Langlois","year":"2018","journal-title":"Clin Chem"},{"key":"10.1016\/j.cjca.2021.03.016_bib0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.atherosclerosis.2019.12.005","article-title":"Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM","volume":"294","author":"Nordestgaard","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2021.03.016_bib0046","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1194\/jlr.E066985","article-title":"Lipoprotein (a): coming of age at last","volume":"57","author":"Witztum","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.cjca.2021.03.016_bib0047","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.atherosclerosis.2014.01.049","article-title":"Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk","volume":"234","author":"Langsted","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2021.03.016_bib0048","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2021.03.016_bib0049","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2021.03.016_bib0050","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2021.03.016_bib0051","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-lowering by 50 mg\/dL (105 nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0052","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Pare","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2021.03.016_bib0053","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1194\/jlr.R051904","article-title":"Lipoprotein (a): impact by ethnicity and environmental and medical conditions","volume":"57","author":"Enkhmaa","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.cjca.2021.03.016_bib0054","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2021.03.016_bib0056","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0057","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12944-019-1092-6","article-title":"Prognostic value of lipoprotein (a) level in patients with coronary artery disease: a meta-analysis","volume":"18","author":"Wang","year":"2019","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.cjca.2021.03.016_bib0058","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1161\/STROKEAHA.119.026872","article-title":"Causal effect of Lp(a) [lipoprotein(a)] level on ischemic stroke and Alzheimer disease: a Mendelian randomization study","volume":"50","author":"Pan","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.cjca.2021.03.016_bib0059","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0060","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/0003319716637792","article-title":"Lipoprotein(a) levels in patients with abdominal aortic aneurysm","volume":"68","author":"Kotani","year":"2017","journal-title":"Angiology"},{"key":"10.1016\/j.cjca.2021.03.016_bib0061","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1016\/j.jacc.2015.09.089","article-title":"Primary prevention with statins: ACC\/AHA risk-based approach versus trial-based approaches to guide statin therapy","volume":"66","author":"Mortensen","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0062","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamacardio.2019.3665","article-title":"Statin use in primary prevention of atherosclerotic cardiovascular disease according to 5 major guidelines for sensitivity, specificity, and number needed to treat","volume":"4","author":"Mortensen","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0063","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jcmg.2017.01.029","article-title":"Statin trials, cardiovascular events, and coronary artery calcification: implications for a trial-based approach to statin therapy in MESA","volume":"11","author":"Mortensen","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2021.03.016_bib0064","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1161\/CIRCIMAGING.113.000341","article-title":"Is there a role for coronary artery calcium scoring for management of asymptomatic patients at risk for coronary artery disease?: Clinical risk scores are not sufficient to define primary prevention treatment strategies among asymptomatic patients","volume":"7","author":"Blaha","year":"2014","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2021.03.016_bib0065","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1093\/eurheartj\/eht508","article-title":"Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the Multi-Ethnic Study of Atherosclerosis","volume":"35","author":"Silverman","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2021.03.016_bib0066","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.jcmg.2019.08.024","article-title":"Interplay of coronary artery calcium and risk factors for predicting CVD\/CHD mortality: the CAC Consortium","volume":"13","author":"Grandhi","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2021.03.016_bib0067","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1016\/j.jacc.2011.10.851","volume":"58","author":"Villines","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0068","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010471","article-title":"Race\/ethnicity and the prognostic implications of coronary artery calcium for all-cause and cardiovascular disease mortality: the Coronary Artery Calcium Consortium","volume":"7","author":"Orimoloye","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjca.2021.03.016_bib0069","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.jacc.2015.08.035","volume":"66","author":"McClelland","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/heartjnl-2011-300747","article-title":"Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review","volume":"98","author":"Peters","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2021.03.016_bib0071","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2012.9624","article-title":"Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals","volume":"308","author":"Yeboah","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2021.03.016_bib0072","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jacc.2018.05.027","article-title":"Coronary calcium score and cardiovascular risk","volume":"72","author":"Greenland","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0073","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jcmg.2016.03.022","article-title":"CAC score improves coronary and CV risk assessment above statin indication by ESC and AHA\/ACC primary prevention guidelines","volume":"10","author":"Mahabadi","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2021.03.016_bib0074","doi-asserted-by":"crossref","first-page":"214","DOI":"10.21037\/cdt.2019.04.05","article-title":"Reclassification of coronary heart disease risk in a primary prevention setting: traditional risk factor assessment vs. coronary artery calcium scoring","volume":"9","author":"Alashi","year":"2019","journal-title":"Cardiovasc Diagn Ther"},{"key":"10.1016\/j.cjca.2021.03.016_bib0075","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.jacc.2010.07.005","volume":"56","author":"Taylor","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0076","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jcmg.2008.12.031","article-title":"Diagnostic and prognostic value of absence of coronary artery calcification","volume":"2","author":"Sarwar","year":"2009","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2021.03.016_bib0077","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2019.11.008","article-title":"All-cause and cause-specific mortality in individuals with zero and minimal coronary artery calcium: a long-term, competing risk analysis in the Coronary Artery Calcium Consortium","volume":"294","author":"Blaha","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2021.03.016_bib0078","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.atherosclerosis.2010.12.014","article-title":"Coronary artery calcium score improves cardiovascular risk prediction in persons without indication for statin therapy","volume":"215","author":"Mohlenkamp","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2021.03.016_bib0079","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1093\/eurheartj\/ehy217","article-title":"Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA)","volume":"39","author":"Budoff","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2021.03.016_bib0080","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jcmg.2012.02.017","article-title":"Mortality rates in smokers and nonsmokers in the presence or absence of coronary artery calcification","volume":"5","author":"McEvoy","year":"2012","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2021.03.016_bib0081","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.amjcard.2014.07.043","article-title":"Significance of a positive family history for coronary heart disease in patients with a zero coronary artery calcium score (from the Multi-Ethnic Study of Atherosclerosis)","volume":"114","author":"Cohen","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0082","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jcct.2019.03.012","article-title":"Coronary artery calcium scoring in low risk patients with family history of coronary heart disease: validation of the SCCT guideline approach in the coronary artery calcium consortium","volume":"13","author":"Dudum","year":"2019","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.cjca.2021.03.016_bib0083","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jacc.2009.08.088","article-title":"Determinants of coronary calcium conversion among patients with a normal coronary calcium scan: what is the \u201cwarranty period\u201d for remaining normal?","volume":"55","author":"Min","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0084","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.jacc.2011.01.019","article-title":"Impact of coronary artery calcium scanning on coronary risk factors and downstream testing the EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) prospective randomized trial","volume":"57","author":"Rozanski","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0085","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jcmg.2017.01.030","article-title":"The identification of calcified coronary plaque is associated with initiation and continuation of pharmacological and lifestyle preventive therapies: a systematic review and meta-analysis","volume":"10","author":"Gupta","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2021.03.016_bib0086","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.jcmg.2018.09.019","article-title":"Coronary artery calcium and cardiovascular events in patients with familial hypercholesterolemia receiving standard lipid-lowering therapy","volume":"12","author":"Miname","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2021.03.016_bib0087","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/ehjci\/jez280","article-title":"Vascular age derived from coronary artery calcium score on the risk stratification of individuals with heterozygous familial hypercholesterolaemia","volume":"21","author":"Miname","year":"2019","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2021.03.016_bib0088","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.jacc.2015.01.036","article-title":"Impact of statins on serial coronary calcification during atheroma progression and regression","volume":"65","author":"Puri","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0089","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jcmg.2017.04.014","article-title":"Implications of coronary artery calcium testing for treatment decisions among statin candidates according to the ACC\/AHA cholesterol management guidelines: a cost-effectiveness analysis","volume":"10","author":"Hong","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2021.03.016_bib0090","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2021.03.016_bib0091","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2021.03.016_bib0092","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2021.03.016_bib0093","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2021.03.016_bib0094","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2021.03.016_bib0095","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2021.03.016_bib0096","first-page":"e1082","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2021.03.016_bib0097","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2021.03.016_bib0098","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2021.03.016_bib0099","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2021.03.016_bib0100","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2021.03.016_bib0101","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2021.03.016_bib0102","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1161\/CIRCULATIONAHA.117.032615","article-title":"High-dose versus low-dose pitavastatin in Japanese Patients with stable coronary artery disease (REAL-CAD). A randomized superiority trial","volume":"137","author":"Taguchi","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2021.03.016_bib0103","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1910355","article-title":"A comparison of two LDL cholesterol targets after ischemic stroke","volume":"382","author":"Amarenco","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2021.03.016_bib0104","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2021.03.016_bib0105","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0106","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2021.03.016_bib0107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamacardio.2020.0882","article-title":"Efficacy of evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: a prespecified secondary analysis from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) trial","volume":"5","author":"Gencer","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0108","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0109","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamacardio.2020.3151","volume":"6","author":"Deedwania","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0110","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","article-title":"Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial","volume":"7","author":"Ray","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0111","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease. Insights from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Trial. Circulation"},{"key":"10.1016\/j.cjca.2021.03.016_bib0112","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jacc.2019.03.013","article-title":"Alirocumab in patients with polyvascular disease and recent acute coronary syndrome. ODYSSEY OUTCOMES Trial","volume":"74","author":"Jukkema","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0113","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","article-title":"Clinical benefit of evolocumab by severity and extent of coronary artery disease: analysis from Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER)","volume":"138","author":"Sabatine","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2021.03.016_bib0114","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jacc.2019.07.015","article-title":"Effects of alirocumab on cardiovascular events after coronary bypass surgery","volume":"74","author":"Goodman","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0115","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0116","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2021.03.016_bib0117","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jacc.2016.11.037","article-title":"Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials","volume":"69","author":"Robinson","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0118","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1080\/14740338.2019.1681395","article-title":"Efficacy and safety of PCSK9 monoclonal antibodies","volume":"18","author":"Iqbal","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cjca.2021.03.016_bib0119","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/eurheartj\/ehx162","article-title":"Low-density lipoprotein cholesterol targeting with pitavastatin\u202f+\u202fezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial","volume":"38","author":"Hagiwara","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2021.03.016_bib0120","first-page":"1552","article-title":"Monoclonal antibodies for the treatment of hypercholesterolemia: targeting PCSK9","volume":"32","author":"Alkindi","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0121","first-page":"1600","article-title":"Cardiovascular efficacy and safety of PCSK9 inhibitors: systematic review and meta-analysis including the ODYSSEY OUTCOMES Trial","volume":"34","author":"Turgeon","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0122","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0123","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2021.03.016_bib0124","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2021.03.016_bib0125","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n-3 fatty acid supplements in diabetes mellitus","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2021.03.016_bib0126","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1811403","article-title":"Marine n-3 fatty acids and prevention of cardiovascular disease and cancer","volume":"380","author":"Manson","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2021.03.016_bib0127","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2021.03.016_bib0128","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2021.03.016_bib0129","unstructured":"ClinicalTrials.gov. Effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VERSALIUS-CV). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03872401. Accessed September 3, 2020."},{"key":"10.1016\/j.cjca.2021.03.016_bib0130","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2021.03.016_bib0131","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2021.03.016_bib0132","unstructured":"ClinicalTrials.gov. A randomized trial assessing the effects of inclisiran on clinical outcomes among people with cardiovascular disease (ORION-4). Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03705234. Accessed September 3, 2020."},{"key":"10.1016\/j.cjca.2021.03.016_bib0133","unstructured":"ClincalTrials.gov. Effect of dalcetrapib vs placebo on CV risk on a genetically defined population with a recent ACS (dal-GenE). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02525939. Accessed September 3, 2020."},{"key":"10.1016\/j.cjca.2021.03.016_bib0134","unstructured":"ClinicalTrials.gov. Evaluation of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant treated with bempedoic acid (ETC-1002) or placebo (CLEAR Outcomes). Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02993406. Accessed September 3, 2020."},{"key":"10.1016\/j.cjca.2021.03.016_bib0135","unstructured":"ClinicalTrials.gov. Pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03071692. Accessed September 3, 2020."},{"key":"10.1016\/j.cjca.2021.03.016_bib0136","first-page":"1553","article-title":"Canadian Cardiovascular Society position statement on familial hypercholesterolemia: update 2018","volume":"34","author":"Brunham","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0137","first-page":"1540","article-title":"Effects of n-3 fatty acid supplements in diabetes mellitus","volume":"9","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2021.03.016_bib0138","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1811403","article-title":"Marine n-3 fatty acids and prevention of cardiovascular disease and cancer","volume":"380","author":"Manson","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2021.03.016_bib0139","article-title":"Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease","volume":"11","author":"Abdelhamid","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cjca.2021.03.016_bib0140","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3945\/jn.111.148973","article-title":"A meta-analysis shows that docosahexaenoic acid from algal oil reduces serum triglycerides and increases HDL-cholesterol and LDL-cholesterol in persons without coronary heart disease","volume":"142","author":"Bernstein","year":"2012","journal-title":"J Nutr"},{"key":"10.1016\/j.cjca.2021.03.016_bib0141","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijcard.2008.03.092","article-title":"Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis","volume":"136","author":"Eslick","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2021.03.016_bib0142","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2006.02.012","article-title":"Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review","volume":"189","author":"Balk","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2021.03.016_bib0143","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1203859","article-title":"N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia","volume":"367","author":"Bosch","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X21001653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X21001653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:46:33Z","timestamp":1760107593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X21001653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":141,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0828282X21001653"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2021.03.016","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2021.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}